Not yet recruiting
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
NCT07484139
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Cancer, +7 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
- Thomas Jefferson University Philadelphia, Pennsylvania, United States